Navigation Links
Epitope in Medical Technology

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B cells.(4) This epitope is different from the binding sites targeted by other CD20 antibodies ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... research and development activities with its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) technology. L.E.A.P.S.(TM) is a novel T-cell ... peptides. The L.E.A.P.S.(TM) constructs containing the antigenic disease epitope linked to a T-cell binding ligand (TCBL) can be manufactured by peptide ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

... fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 molecule on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 molecule. Ofatumumab is being developed to treat CLL, ...

Genmab Reaches Milestone in Ofatumumab Collaboration

... next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different from the other anti-CD20 antibodies currently available or in ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that is a key component of the disease. ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... About Ofatumumab Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. Ofatumumab also binds to the large loop of the CD20 molecule. ...

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and ...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, ...

Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment

... nearly 10% of Europeans suffering from the condition. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit ...

Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

... and their physicians." Ofatumumab is an investigational new generation fully human monoclonal antibody that uniquely targets the small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular ...

IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease. About Type 1 ...

ARIUS to Present at American Association for Cancer Research Annual Meeting

... of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties." Novel antibody ARH460-16-2 recognizes an epitope of CD44 that is highly expressed in liver cancers. Abstract 662, Section 27, Board 15, Sunday, Apr 15, 8AM - 12PM ARH460-16-2, a functional ...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

... IMC-EB10, NC7, and D4-3 (Anti-FLT3 MAb) (#4110 Williams et al. Elucidation of the antagonistic mechanisms of various anti-FLT3 antibodies via binding epitope dissection.) -- IMC-D11 (anti-FGFR3 MAb) (#2080 DiRenzo et al. Neutralizing antibody against FGFR3 shows anti-tumor effects in multiple ...

IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting

... the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004. ...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

... indicate therapy of tumors can be achieved with 500 microCi of Y-90 or less. About hPAM4 hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies with ...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

... infection. The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of ...
Other Contents
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... August 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can ... can’t afford to start a business.” Neither needs be a major obstacle. , The ... to start a business and be successful. The risks of starting a business can be ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
Other TagsOther Tags